GW Pharmaceuticals won historic FDA approval back in June when the agency green-lighted its cannabidiol drug Epidiolex to treat rare and severe forms of epilepsy. But the new medication has been stuck in the starting gate, waiting for the Drug Enforcement Administration to decide how to handle the first-of-its kind drug.
Now, the DEA has made its move. GW reported Epidiolex will move from Schedule I to Schedule V, the DEA's lowest—and most favorable for the drug's rollout. Authorities can now finalize its label and the company can request a Schedule V license to sell it.